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Sudden Cardiac Death Due to Deficiency
of the Mitochondrial Inorganic Pyrophosphatase PPA2
Hannah Kennedy,1,2,20 Tobias B. Haack,3,4,20 Verity Hartill,5,20 Lavinija Matakovic,6,20
E. Regula Baumgartner,7 Howard Potter,1 Richard Mackay,1 Charlotte L. Alston,8 Siobhan O’Sullivan,9
Robert McFarland,8 Grainne Connolly,10 Caroline Gannon,11 Richard King,1 Scott Mead,1,22
Ian Crozier,12 Wandy Chan,12,13 Chris M. Florkowski,1 Martin Sage,14,23 Thomas Ho¨fken,15
Bader Alhaddad,3,4 Laura S. Kremer,3,4 Robert Kopajtich,3,4 Rene´ G. Feichtinger,6 Wolfgang Sperl,6
Richard J. Rodenburg,16 Jean Claude Minet,17 Angus Dobbie,18 Tim M. Strom,3,4
Thomas Meitinger,3,4,19 Peter M. George,1,2,* Colin A. Johnson,5 Robert W. Taylor,8,21
Holger Prokisch,3,4,21 Kit Doudney,1,2,21 and Johannes A. Mayr6,21,*
We have used whole-exome sequencing in ten individuals from four unrelated pedigrees to identify biallelic missense mutations in the
nuclear-encoded mitochondrial inorganic pyrophosphatase (PPA2) that are associated with mitochondrial disease. These individuals
show a range of severity, indicating that PPA2mutations may cause a spectrum of mitochondrial disease phenotypes. Severe symptoms
include seizures, lactic acidosis, cardiac arrhythmia, and death within days of birth. In the index family, presentation was milder and
manifested as cardiac fibrosis and an exquisite sensitivity to alcohol, leading to sudden arrhythmic cardiac death in the second decade
of life. Comparison of normal and mutant PPA2-containing mitochondria from fibroblasts showed that the activity of inorganic pyro-
phosphatase was significantly reduced in affected individuals. Recombinant PPA2 enzymesmodeling hypomorphic missensemutations
had decreased activity that correlatedwith disease severity. These findings confirm the pathogenicity of PPA2mutations and suggest that
PPA2 is a cardiomyopathy-associated protein, which has a greater physiological importance in mitochondrial function than previously
recognized.Inorganic pyrophosphate (PPi, also termed diphosphate) is
formed by several important nucleotide triphosphate-
dependent reactions necessary for DNA, RNA, protein,
and lipid synthesis. Pyrophosphate has to be hydrolyzed
to orthophosphate (Pi). An enzyme that catalyzes this reac-
tion is termed inorganic pyrophosphatase (PPA [Enzyme
Commission number EC 3.6.1.1]) and provides Pi for bio-
molecules via synthesis of ATP, the terminal product of
cellular energy metabolism. PPAs are found in all king-
doms of life. Type I enzymes present in Escherichia coli
and eukaryotes depend on divalent ions, preferably Mg2þ
ions.1 Humans, similar to the yeast Saccharomyces cerevi-
siae, have two PPAs that share sequence homology. These
comprise a cytoplasmic soluble PPA1 and a mitochon-
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ized inner mitochondrial membrane protein.2 Knockout
of the cytoplasmic PPA1 (MIM: 179030) ortholog IPP1
leads to a loss of viability in yeast.3,4 Knockout of the mito-
chondrial PPA2 results in a growth defect on non-ferment-
able carbon sources and loss of mitochondrial DNA in
S. cerevisiae.3
We have identified hypomorphic missense mutations in
the human gene of themitochondrial inorganic pyrophos-
phatase encoded by PPA2 (MIM: 609988) in a multicenter
study by exploring undiagnosed cases with presumed
mitochondrial disease using whole-exome sequencing
(WES). In agreement with the Declaration of Helsinki,
informed consent for genetic and biochemical studies
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Figure 1. Pedigree Structure, PPA2 Genomic Organization Conservation, and Family 1 Variant Modeling
(A) Pedigrees of four families identified with mutations in PPA2 (GenBank: NM_176869.2) encoding the mitochondrial inorganic pyro-
phosphatase. Individuals with a question mark have not been tested. Mutations found in more than one family are colored.
(B) Location of mutations within the gene, and phylogenetic conservation of the predicted missense mutations.
(C) Space fill model showing position of p.Pro228 at boundary of dimers and p.Glu172 in the active site produced in CN3D with refer-
ence PDB: 1M38.
(D) Left: Structural model of one molecule of PPA2 showing the position of four mutations in folded structure (red). Residues that are
known to be critical to PPA2 function in S. cerevisiae are highlighted in yellow.19 Right: Space fill of the PPA2 active site showing three
substitutions are located at the surface of the active site. Models produced using Swiss-PdbViewer20 (with reference PDB: 1M38).The study was approved by the Ethics Committee of the
Technische Universita¨t Mu¨nchen and South Yorkshire
Research Ethics Committee.
Family 1 consists of four affected individuals (P1–P4)
born to healthy unrelated parents of European descent
fromNew Zealand (Figure 1). This family was identified af-
ter the sudden death of two children. The first child, P1,
was well until the age of 15 years when he collapsed and
died after ingestion of a small volume of beer. He had
no prior cardiac symptoms, but had exhibited exquisite
sensitivity to alcohol in medicine and food, which wasThe Americancommon to all four siblings in childhood. This was
manifest by pallor and severe chest and arm pain after
consumption of small amounts of alcohol (<0.1 g
ethanol). The only abnormalities observed post mortem
were in the heart, with both ventricles found to be
slightly dilated. A diagnosis of myocarditis and sudden
arrhythmic cardiac death was made. Individual P3 died
suddenly at 20 years of age after ingestion of a small
amount of alcohol (approx. 10 g ethanol). He was previ-
ously well and had no prior cardiac symptoms, but had
also been exquisitely sensitive to alcohol. At post mortemJournal of Human Genetics 99, 674–682, September 1, 2016 675
Figure 2. Cardiac Fibrosis in PPA2 Defi-
ciency
(A) Affected individual P3, post mortem
section through left ventricle showing a
virtually circumferential lamina of scarring
inmidmyocardiumwith focal subendocar-
dial involvement. Fibrosis is marked by
arrows.
(B and C) Low-power (B) (bar equals 1mm)
and high-power (C) (bar equals 25 mm)mi-
croscopy of the posterior freewall of the
left ventricle showing prominent mid-
myocardial loose fibrosis in P3 (hematoxy-
lin and eosin staining).
(D) Cardiac MRI showing prominent mid-
myocardial fibrosis in affected individual
P4 (at 25 years of age), marked by arrows.examination the heart weighed 395 g (normal 300 g). The
left ventricle was dilated with a virtually circumferential
lamina of scarring in mid-myocardium. Microscopic ex-
amination revealed very widespread, mostly mature scar-
ring of mid-myocardium in all sectors (Figure 2). Two
living siblings, P2 and P4 (currently 38 and 34 years of
age, respectively) were assessed based on their family his-
tory and their sensitivity to alcohol. Cardiac MRI showed
marked mid-myocardial fibrosis in both siblings (P4
shown in Figure 2). They subsequently each received an
implantable defibrillator for primary prophylaxis of sud-
den arrhythmic cardiac death, although no events have
occurred to date. Despite extensive investigations into
the cause of sudden death in this family over a period of
>20 years, no definitive diagnosis was made (for more
clinical details see Supplemental Data).
Whole-exome sequencing (see Table S1 for details) was
performed on the two living siblings to elucidate the un-
derlying molecular defect. Given that both parents ap-
peared unaffected, we searched for rare non-synonymous
variants common to the two affected children in a reces-
sive disease model of inheritance. Four candidate genes
were identified with compounding missense mutations
and with an association to cardiomyopathy and/or mito-
chondrial function: KCNJ12 (MIM: 602323), TTN (MIM:
188840), AARS2 (MIM: 612035), and PPA2. Of these four
genes, variants in all but PPA2 were excluded based on
non-segregation with disease (Table S2). Both affected
children were compound heterozygous for PPA2 muta-
tions c.[514G>A];[683C>T] causing the predicted coding
changes p.[Glu172Lys];[Pro228Leu], with each parent
carrying one mutation. Sanger sequencing confirmed676 The American Journal of Human Genetics 99, 674–682, September 1, 2016compound heterozygosity of PPA2
mutations in the two deceased indi-
viduals, establishing the same geno-
type for all four affected individuals
(Figure S1).
We considered that PPA2 dysfunc-
tion was the likely underlying cause
of sudden cardiac death in our
index family. We identified anadditional three families with a further six affected individ-
uals harboring compound heterozygous or homozygous
PPA2 mutations (Figure 1) in large exome datasets from
individuals suspected of a disorder in mitochondrial
energy metabolism. Family 2 (c.[500C>T];[500C>T],
p.[Pro167Leu];[Pro167Leu]) (GenBank: NM_176869.2)
comprises three affected siblings born to consanguineous
parents from Sri Lanka. Family 3 (c.[500C>T];[500C>T],
p.[Pro167Leu];[Pro167Leu]) consists of two affected and
two healthy siblings born to consanguineous parents
of Pakistani origin. Family 4 (c.[380G>T];[514G>A],
p.[Arg127Leu];[Glu172Lys]) has one affected and one
healthy sibling born to unrelated healthy parents from
the United Kingdom.
Unlike the individuals from family 1, all the affected in-
dividuals in these three families presented with classical
mitochondrial disease symptoms and died within the
first 2 years of life of cardiac failure (Table 1). The
identification of these individuals suggests that a
spectrum of severity is conferred by different biallelic
PPA2 mutations. In affected individuals homozygous for
c.500C>T (p.Pro167Leu), the clinical presentation
involved lactic acidosis, seizures, hypotonia, and cardiac
arrhythmia within the first months of life. Myocyte loss,
disarray, or fibrosis was present in all individuals.
Respiratory chain function varied from normal to
moderate reduction in complex I and IV activities in
cardiac tissue and was normal in fibroblasts and skeletal
muscle tissue. The individual harboring compound hetero-
zygous c.[380G>T];[514G>A], p.[Arg127Leu];[Glu172Lys]
mutations first presented with short seizures at 10 months
and developed dilated cardiomyopathy and multiorgan
Table 1. Genetic and Clinical Findings in Individuals with PPA2 Variants
ID Sex (M/F)
PPA2 Variants: cDNA
(NM_176869.2), Protein
(NP_789845.1)
OXPHOS Activities (Normal
Ranges in Brackets)
Clinical Features
Other FindingsAO Age at Death Cardiac Phenotype
F1, II:1, P1 M c.[514G>A];[683C>T],
p.[Glu172Lys];[Pro228Leu]
ND 4 years 15 years autopsy: slight dilation of both
ventricles; small pale area in the
epicardium of the left ventricle,
evidence of focal inflammation
with neutrophils, lymphocytes,
and eosinophils
sensitive to small amounts of
alcohol
F1, II:2, P2 M c.[514G>A];[683C>T],
p.[Glu172Lys];[Pro228Leu]
ND 14 years alive at 38 years cardiac MRI: myocardial fibrosis;
received implantable defibrillator
sensitive to small amounts of
alcohol
F1, II:3, P3 M c.[514G>A];[683C>T],
p.[Glu172Lys];[Pro228Leu]
ND 10 years 20 years autopsy: dilation of the left
ventricle, circumferential lamina
of scarring in midmyocardium
with focal subendocardial
involvement; very widespread
mostly mature scarring of
midmyocardium in all sectors
sensitive to small amounts of
alcohol
F1, II:4, P4 F c.[514G>A];[683C>T],
p.[Glu172Lys];[Pro228Leu]
normal in skeletal muscle 9 years alive at 33 years cardiac MRI: myocardial fibrosis;
received implantable defibrillator.
sensitive to small amounts of
alcohol; immunohistochemical
studies of skeletal muscle showed
changes suggestive of a mild
chronic myopathy
F2, II:, P5 M c.[500C>T];[500C>T],
p.[Pro167Leu];[Pro167Leu]
ND 10 days 11 days autopsy: herds of fresh necrosis
mainly of the right heart and
interstitial lymphocyte
infiltration; electron microscopy:
myocard showed mitochondria
with degeneration of cristae
elevated plasma lactate levels;
tachypnoea and tachycardia;
tonic-clonic seizures; death after
severe bradycardia
F2, II:2, P6 F c.[500C>T];[500C>T],
p.[Pro167Leu];[Pro167Leu]
normal in skeletal muscle and
fibroblasts
14 days 14 days autopsy: acute and subacute
necrosis more pronounced in the
right heart more severe than in
the left heart; electron
microscopy: myocardium showed
mitochondria with degeneration
of cristae like in P5
metabolic acidosis with elevated
plasma lactate levels; tachypneoa;
vomiting, generalized seizure;
cardio-respiratory
decompensation; death 6.5 hr
after onset of symptoms; multiple
subacute necroses in the semioval
center of both cerebral
hemispheres
F2, II:3, P7 M c.[500C>T];[500C>T],
p.[Pro167Leu];[Pro167Leu]
normal in skeletal muscle and
fibroblasts; heart muscle: LV: CI
4.1 (5.5–51.5) and CIV 64
(73.2–516.6) decreased, RV:
CI not detectable, CII 9.0
(25.8–40.7), CIV 42 (73.2-516.6)
3 days 32 days cardiac tachyarrhythmia; ECG
showed hypodynamic right
ventricle; autopsy: myocardium
without necrosis and
inflammatory infiltrations;
myocytes with reduced amount
of myofibrils; region of fibrosis,
partially fat tissue in the right
heart
elevated plasma lactate,
transaminases, lactate
dehydrogenase, creatine kinase
(CK), CK-MB, and troponin levels
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678 The American Journal of Human Genetics 99, 674–682, Septembfailure at 1 year, necessitating intensive care for several
weeks. All affected individuals died from cardiac failure af-
ter sudden deterioration. Interestingly, both individuals
from family 3 and the affected individual from family 4
had viral infections at the time of hospital admission
before their final heart failure (Figure S2). In the older sib-
lings from family 2, vomiting (among other symptoms of
metabolic decompensation prior to admission) was re-
ported, one of them having loose stools once, but viral
infection was not confirmed (Table 1). Clinical case his-
tories of all affected individuals are provided in the Supple-
mental Data.
Western blotting showed normal amounts of PPA2 pro-
tein in fibroblast mitochondria from individuals P5, P6,
and P7 but decreased amount in P9 (Figure S3). In autopsy
muscle of P9, the amount of PPA2 protein was decreased,
although it appeared to be normal in P6, who carried the
same PPA2 mutation (Figure S4). In heart autopsy material
from P10, we noted decreased PPA2 levels as well as
decreased levels of a complex I structural protein (subunit
NDUFS4), correlating with the observed decrease in com-
plex I activity in this tissue (Figure S5). In the cardiac au-
topsy sample of P7, PPA2 and complex I subunit levels
were decreased as was the expression of the mitochondrial
marker proteins porin and citrate synthase, suggestive of a
more general reduction of mitochondrial number possibly
due to changes in tissue composition (Figure S5).
All four missense variants involve residues of high evolu-
tionary conservation (Figure 1) and are predicted to have a
pathogenic effect on PPA2 function in silico (SIFT, Poly-
Phen-2, and MutationTaster) (Table S3). The high homol-
ogy between the human and yeast (S. cerevisiae) PPA
proteins facilitated predictive modeling of these human
variants based on the known yeast structure of the cyto-
solic/nuclear pyrophosphatase IPP1 (MMDB ID: 21720;
PDB: 1M38) (Figure 1). Glutamine to lysine substitution
at residue 172 is predicted to disrupt at least three
hydrogen bonds between interacting protein chains near
the surface of the enzyme’s active site. Any disruption of
the active site may impair enzymatic function of PPA2. A
substitution of proline to leucine at residue 228, located
on the outside surface where dimer association occurs, is
also predicted to disrupt the secondary structure of PPA2.
Proline is a known peptide turning point amino acid and
is likely to affect the orientation of the two helices between
which it lies in this enzyme. We suggest that disruption of
the conformation of the outer surface may impair correct
dimerization of PPA2 molecules.
All four PPA2 mutations identified in our cohort are
present in the Exome Aggregation Consortium (ExAC)
database (12/2015) at a frequency < 0.005, equating to
59/60,400 individuals heterozygous for p.Glu172Lys,
30/60,134 individuals heterozygous for p.Pro228Leu,
20/60,677 individuals heterozygous for p.Arg127Leu, and
3/60,457 individuals heterozygous for p.Pro167Leu (Table
S1). None of these PPA2 variants is reported in a homozy-
gous state in ExAC, the NHLBI Exome Sequencing Projecter 1, 2016
(ESP6500) database, or 7,000 control exomes of an in-
house database (Munich). Due to the complete growth
defect of yeast PPA2 knockouts on non-fermentable carbon
sources, it can be speculated that biallelic loss-of-function
mutations of PPA2 are incompatible with life in humans.
In total, 13 LOF variants (found in 18 alleles) are published
in the ExAC database and furthermore ExAC contains 71
different missense mutations (in 237 alleles) with a SIFT
score% 0.05 (cut-off for mutations to be considered path-
ogenically relevant). The cumulative heterozygous carrier
frequency of these likely pathogenic PPA2 mutations
is 0.0024, which would result in a calculated prevalence
for compound heterozygous or homozygous pathogenic
PPA2 mutations of 0.58 per 100,000 (1 in 170,000).
In order to investigate effects of PPA2 deficiency on the
cellular metabolism, we measured oxygen consumption
rate (OCR) by micro scale respirometry (XF96 Seahorse
Biosciences).5 Basal respiration and oligomycin-inhibited
OCR was similar in affected individuals (P5, P6, and P7)
but after the addition of the mitochondrial uncoupler
FCCP, a higher activity was observed in affected individ-
uals compared to control subjects. The difference between
basal and FCCP-stimulated OCR, termed reserve respira-
tory capacity (RRC), was twice as high in PPA2-deficient
fibroblasts compared to controls (Figures S6A and S6B).
High RRC observed in PPA2-deficient cells might be due
to a limitation in ATP synthesis because of insufficient Pi
supply within mitochondria (Figure S7). Actually, the
investigation of cells with proven ATP synthase deficiency
due to mutations in either TMEM706 (MIM: 612418) or
ATP5E7 (MIM: 606153) revealed a similar OCR-profile
with high RRC. Because high RRC is not a specific finding,
further investigations were required to demonstrate
decreased ATP synthesis in PPA2 deficiency.
We next determined pyrophosphatase activity in iso-
latedmitochondria from fibroblasts of control and affected
individuals, which were prepared from 540 ccm of
confluent primary fibroblasts. After harvesting by trypsini-
zation and washing twice with phosphate-buffered saline
cells, the weight of the cell pellet was determined. Cells
were suspended in the 10-fold amount (e.g., 500 mL per
50 mg of cell pellet) of ice-cold, hypotonic homogeniza-
tion buffer (10 mmol/L Tris [pH 7.4]) and homogenized
by the use of a tight fitting Potter Elvehjem homogenizer.
Immediately after homogenization, 1.5 mmol/L sucrose
(20% of the homogenization volume) was added to pre-
serve mitochondria. After centrifugation at 600 3 g, the
mitochondria containing supernatant was centrifuged at
10,000 3 g and the mitochondria-containing pellet was
washed twice with SEKT buffer (250 mmol/L sucrose,
2 mmol/L EGTA, 40 mmol/L KCl, 20 mmol/L KCl [pH
7.4]). The mitochondrial pellet was finally suspended in
the equal amount of SEKT buffer (50 mL per 50 mg cell pel-
let) and stored at 80C prior to further investigations.7,8
The hydrolysis of PPi and quantification of orthophos-
phate (Pi) formed was determined according to previously
published methods9,10 with minor modifications. The in-The Americancubation buffer contained 50 mmol/L Tris ([pH 8.0]
0.1 mmol/L EGTA) and the indicated concentrations of
MgCl2 and PPi. The reaction was started by the addition
of enzyme in a final volume of 100 mL, incubated at
37C, and stopped by the addition of 100 mL reagent A
(0.70% (w/v) ammonium heptamolybdate tetrahydrate,
1.26 mol/L H2SO4), developed by the addition of 40 mL re-
agent B (0.35% (w/v) polyvinylalcohol, 0.035% (w/v) mal-
achite green oxalate at room temperature for 20 min. The
activity of PPAwas significantly decreased in isolated fibro-
blast mitochondria from affected individuals P5, P7, and
P9 at each PPi (0.001–0.1 mmol/L) and MgCl2 (0.5 or
3.0 mmol/L) concentration investigated (Figures 3A and
3B). Inactivation by CaCl2 was similar in affected individ-
uals compared to control subjects (Figure 3C). Fibroblasts
from affected individuals P6 and P10 did not grow suffi-
ciently to collect enough cells for the isolation of mito-
chondria and from individuals P1–P4 and P8 no fibroblasts
were available.
For the expression of recombinant human PPA2, wild-
type PPA2 cDNA was cloned into the expression vector
pRSET B (Invitrogen) using the cloning sites BamHI and
BglII.11 The first 96 nucleotides corresponding to the cleav-
able N-terminal mitochondrial targeting sequence were
omitted from the construct. The c.500C>T (p.Pro167Leu),
c.514G>A (p.Glu172Lys), and c.683C>T (p.Pro228Leu)
variants were introduced into the wild-type PPA2 sequence
by site-directed mutagenesis using Gibson assembly (New
England Biolabs) with appropriate primers for PCR amplifi-
cation (Phusion, New England Biolabs) and the correct cod-
ing regions of all four constructs was confirmed by Sanger
sequencing. Recombinant protein was expressed in the
Escherichia coli strain BL21(DE3)pLysS at 37C starting at
OD600 of 0.2 and using 1 mmol/L IPTG for 2 hr. The bacte-
rial suspension was harvested and sonified in homogeniza-
tion buffer and the supernatant was bound to HisPur cobalt
spin columns (Thermo).11 The amount of the recombinant
proteins was determined by western blotting with a
human PPA2 antibody (Abcam cat# ab177935). Equal
amounts of either wild-type or mutant recombinant PPA2
proteins were used for the pyrophosphatase activity assay.
Compared to wild-type, the p.Pro167Leu and p.Glu172Lys
variants showed 5%–10% residual activity at PPi substrate
concentrations 18–500 mmol/L. The p.Pro228Leu variant
had a residual activity of 24%–28% in this concentration
range compared to wild-type (Figure 3D). The activities of
wild-type andmutants were similarly sensitive to inhibition
by Ca2þ (data not shown).
As previously reported, PPA2 knockout strain from
S. cereviseae is unable to grow on aerobic media.3 We also
detected a growth defect of PPA2 knockout yeast on
diamide-containing media, which lowers antioxidant con-
centrations (Figure S8).12 These antioxidants protect the
cell against reactive oxygen species that are also natural
by-products of mitochondrial respiratory chain function.
The increased diamide sensitivity of PPA2-deficient yeast
therefore suggests reduced levels of antioxidants.Journal of Human Genetics 99, 674–682, September 1, 2016 679
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Figure 3. Inorganic Pyrophosphatase Ac-
tivity in Fibroblast Mitochondria and Re-
combinant Enzymes
(A and B) Activity of inorganic pyrophos-
phatase in different fibroblast mitochon-
dria isolations from affected individuals
(P) P5, P7, and P9 compared to 14 control
subjects (C) at different PPi concentrations
and either (A) 0.5 mmol/L MgCl2 or (B)
3.0 mmol/L MgCl2.
(C) Inhibition of inorganic pyrophospha-
tase in fibroblast mitochondria from
affected individual P5 (red squares) and
three control subjects (black circles)
incubated at 0.5 mmol/L MgCl2 and
different CaCl2 concentrations and either
0.1 mmol/L PPi or 0.01 mmol/L PPi (small
insert).
(D) Pyrophosphatase activity of equal
amounts of recombinant proteins at
different PPi concentrations.
(E) Protein amount of recombinant PPA2
protein was adjusted by western blot anal-
ysis and silver staining (Figure S9).
*p < 0.01, **p < 0.0001 in Student’s un-
paired t test. The error bars in this graph
indicate the standard error of the mean.In the case of family 1, our data suggest that p.Pro228Leu
is a relatively mild variant, given that PPA2 function is
only moderately reduced. This hypothesis is supported by
investigation of the activity of recombinant PPA2 enzyme
activity. The p.Pro228Leu substitution resulted in a reduc-
tion of PPA activity to approximately 25% of wild-type
(Figure 3). These individuals show chronic accumulation
of cardiac fibrosis, and death occurred after ingestion of
alcohol to which they were already known to have acute
sensitivity. We propose that alcohol acted as a trigger in
these case subjects, whose PPA2 dysfunction created
chronic mitochondrial sensitivity and whose hearts were
consistently deprived of adequate ATP resulting in fibrosis.
Ingestion of alcohol appears to have increased the stress on
the already sensitive mitochondria/fibrotic heart, causing
cardiac arrhythmia and death. There is a link between
alcohol metabolism and inorganic pyrophosphatase func-
tion that might underlie the pathology of affected individ-
uals. Ethanol is oxidized to acetaldehyde and further to
acetic acid.13 Resulting acetic acid has to be activated to
acetyl-coenzymeA,which is accompanied by the formation
of equimolar amounts of PPi (Figure S7). This esterification
reaction is catalyzed by short-chain acyl-CoA synthetases
encoded, for example, byACSS1 (MIM: 614355), an enzyme680 The American Journal of Human Genetics 99, 674–682, September 1, 2016with high expression in heart mito-
chondria.14 In cases of severe PPA2
dysfunction, ATP depletion has an
acute effect and lactic acidosis and car-
diomyopathy occurs prior to chronic
damage developing, which could lead
to acute symptoms in the presence of
secondary triggers. It is interesting tonote, however, that both affected individuals in family 3
had a history of vomiting, diarrhea, and seizures prior to
admission to hospital, and viral infection (rotavirus [1st]
and norovirus [2nd]) was confirmed in stool samples taken
at time of admission. A norovirus infection was also found
in P10 from the United Kingdom. This may indicate that a
viral stressor was responsible for adversely affecting mito-
chondrial metabolism in families 3 and 4, in the same
way that alcohol was a trigger for arrhythmia in the index
family. In the oldest sibling of family 2, there was also
some vomiting prior to hospital admission but viral illness
was not confirmed. In the two younger siblings, vomiting
occurred among other initial symptoms of metabolic
compensation, in the youngest sibling who was hospital-
ized from birth already on the third day of life. Of note,
symptoms like vomiting,15 diarrhea,16 and seizures17 are
also typical for other disorders of the mitochondrial energy
metabolism.
All affected individuals died from cardiac failure. Sud-
den, unexpected cardiac death was especially observed in
P1, P3, P5, P6, and P8. As clearly seen in cardiac MRIs
from the two living individuals from family 1, midmyocar-
dial fibrosis is a pre-existing condition (Figure 2) even
though no cardiac symptoms were experienced by these
individuals. Using late gadolinium enhancement (LGE),
myocardial fibrosis can be clearly determined and is also
a common finding in other disorders of the mitochondrial
energy metabolism such as MELAS (MIM: 540000) due to
the common m.3243A>G mutation of the mitochondrial
DNA.18
In conclusion, we have identified biallelic missense
mutations in PPA2 as cause of mitochondrial cardiomy-
opathy and sudden cardiac death. This finding highlights
a critical role of PPA2 in mitochondrial function and
warrants further functional investigation. Importantly,
mild mutations in PPA2 may not have an immediate
life-threatening effect until triggered by a stressor such
as viral illness or alcohol metabolism, predisposing other-
wise healthy individuals to sudden cardiac death.
Considering the relatively high frequency of PPA2 muta-
tions present in the ExAC database, it is important that
clinically suspicious individuals are screened for PPA2
mutations in addition to evidence of heart fibrosis by
cardiac MRI. Moreover, application of an implantable
cardioverter defibrillator may prevent sudden cardiac
death in at-risk individuals who harbor biallelic PPA2
mutations.Supplemental Data
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